 LA JOLLA, Calif., Jan. 22, 2021 GLOBE NEWSWIRE -- Equillium, Inc. Nasdaq: EQ a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b2 EQUATE study of itolizumab in acute graft-versus-host disease aGVHD has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021. 